SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
pcmr12098-sup-0001-FigS1.tifimage/tif269KFigure S1. Map of changes in morphology.
pcmr12098-sup-0002-FigS2.tifimage/tif432KFigure S2. Map of biomarker changes determined by immunohistochemistry.
pcmr12098-sup-0003-FigS3.TIFimage/tif83662KFigure S3. Representative histological images of all patients who had a PRE, EDT, and a PROG biopsy while on BRAF inhibitor treatment (60 × magnification).
pcmr12098-sup-0004-FigS4.jpgimage/jpg16207KFigure S4. Representative images of immunohistological staining for pERK (A, B, C, D, E, F, G, H and I) and Ki-67 expression (J, K, L, M, N, O, P, Q and R) in patients whose best RECIST CT-defined response to BRAF inhibitor treatment was a partial response (patient 3), stable disease (patient 12) and progressive disease (patient 15).
pcmr12098-sup-0005-FigS5.jpgimage/jpg10360KFigure S5. Representative images of immunohistological staining for cyclinD1 (A, B, C, D, E, F, G, H and I) and p27 expression (J, K, L, M, N, O, P, Q and R) in patients whose best RECIST CT-defined response to BRAF inhibitor treatment was a partial response (patient 3), stable disease (patient 12) and progressive disease (patient 15).
pcmr12098-sup-0006-FigS6.jpgimage/jpg6456KFigure S6. Representative images depicting increases in necrosis (A, B, C and D, H & E), apoptosis (E, F, G and H, TUNEL assay) and tumor-infiltrating lymphocytes (I, J, K and L, H & E) from PRE to EDT biopsies.
pcmr12098-sup-0007-TableS1.docxWord document13KTable S1. Details of the primary antibody, antigen retrieval method and detection systems used for immunohistochemical evaluation of human melanoma tissue samples.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.